Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Kanda, Yasunari  [Clear All Filters]
2024
Yanagida S, Kawagishi H, Kanda Y. [Cardiotoxicity risk assessment of anti-cancer drugs and future perspectives]. Nihon Yakurigaku Zasshi. 2024;159(2):83-89.
Yanagida S, Kanda Y. [Prediction of Cardiac Toxicity by Anti-cancer Drugs Using iPSC Cardiomyocytes]. Yakugaku Zasshi. 2024;144(3):265-271.
2023
Li M, Ueyama-Toba Y, Lindley M, Kongklad G, Nawa Y, Kumamoto Y, Ishida S, Kanda Y, Fujita S, Mizuguchi H, et al. Label-Free Evaluation of Maturation and Hepatotoxicity of Human iPSC-Derived Hepatocytes Using Hyperspectral Raman Imaging. Anal Chem. 2023.
2022
Uchiyama Y, Yamazaki D, Kobayashi N, Kanda Y, Sugita-Konishi Y. [Electrophysiological Effect of Citreoviridin on Human InducedPluripotent Stem Cell-derived Cardiomyocytes]. Shokuhin Eiseigaku Zasshi. 2022;63(6):210-217.
Yamada S, Noda T, Okabe K, Yanagida S, Nishida M, Kanda Y. SARS-CoV-2 induces barrier damage and inflammatory responses in the human iPSC-derived intestinal epithelium. J Pharmacol Sci. 2022;149(3):139-146.
2020
Kamata S, Hashiyama R, Hana-Ika H, Ohkubo I, Saito R, Honda A, Anan Y, Akahoshi N, Noguchi K, Kanda Y, et al. Cytotoxicity comparison of 35 developmental neurotoxicants in human induced pluripotent stem cells (iPSC), iPSC-derived neural progenitor cells, and transformed cell lines. Toxicol In Vitro. 2020:104999.
Gintant G, Kaushik EPfeiffer, Feaster T, Stoelzle-Feix S, Kanda Y, Osada T, Smith G, Czysz K, Kettenhofen R, Lu HRong, et al. Repolarization studies using human stem cell-derived cardiomyocytes: Validation studies and best practice recommendations. Regul Toxicol Pharmacol. 2020:104756.
Fukushima H, Yoshioka M, Kawatou M, López-Dávila V, Takeda M, Kanda Y, Sekino Y, Yoshida Y, Yamashita JK. Specific induction and long-term maintenance of high purity ventricular cardiomyocytes from human induced pluripotent stem cells. PLoS One. 2020;15(11):e0241287.
2019
Satsuka A, Kanda Y. Cardiotoxicity assessment of drugs using human iPS cell-derived cardiomyocytes: From proarrhythmia risk to cardiooncology. Curr Pharm Biotechnol. 2019.
Izumi-Nakaseko H, Fujiyoshi M, Hagiwara-Nagasawa M, Goto A, Chiba K, Kambayashi R, Naito AT, Ando K, Kanda Y, Ishii I, et al. Dasatinib can Impair Left Ventricular Mechanical Function But May Lack Proarrhythmic Effect: A Proposal of Non-clinical Guidance for Predicting Clinical Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors. Cardiovasc Toxicol. 2019.
2018
Blinova K, Dang Q, Millard D, Smith G, Pierson J, Guo L, Brock M, Lu HRong, Kraushaar U, Zeng H, et al. International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment. Cell Rep. 2018;24(13):3582-3592.
2015
Asakura K, Hayashi S, Ojima A, Taniguchi T, Miyamoto N, Nakamori C, Nagasawa C, Kitamura T, Osada T, Honda Y, et al. Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes. J Pharmacol Toxicol Methods. 2015.
2014
Hirata N, Yamada S, Shoda T, Kurihara M, Sekino Y, Kanda Y. Sphingosine-1-phosphate promotes expansion of cancer stem cells via S1PR3 by a ligand-independent Notch activation. Nat Commun. 2014;5:4806.